Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Wild-type, human Aβ1-42 peptide. This product is supplied in a form that is not neurotoxic prior to a pre-incubation step. The level of toxicity has been shown to correlate to the extent of β sheet structure.
Catalogue Number
PP69
Brand Family
Calbiochem®
Synonyms
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
References
References
Citron, M., et al. 1997. Nature Med.3, 67. Hardy, J. 1997. Trends in Neurosci.20, 154. Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA94, 4109. Duff, K., et al. 1996. Nature 383, 710. Iwatsubo, T., et al. 1994. Neuron13, 45. Suzuki, N., et al. 1994. Science264, 133. Simmons, L.K., et al. 1994. Mol. Pharmacol.45, 373.
Product Information
Form
Lyophilized
Formulation
Supplied as a chloride salt.
Hill Formula
C₂₀₃H₃₁₂N₅₆O₅₉S
Chemical formula
C₂₀₃H₃₁₂N₅₆O₅₉S
Hygroscopic
Hygroscopic
Preservative
None
Region
Synthetic peptide corresponding to amino acid residues 1 - 42 of the processed human β-amyloid peptide.
Citron, M., et al. 1997. Nature Med.3, 67. Hardy, J. 1997. Trends in Neurosci.20, 154. Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA94, 4109. Duff, K., et al. 1996. Nature 383, 710. Iwatsubo, T., et al. 1994. Neuron13, 45. Suzuki, N., et al. 1994. Science264, 133. Simmons, L.K., et al. 1994. Mol. Pharmacol.45, 373.
数据表
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
26-October-2007 JSW
Synonyms
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Application
Substrate Cleavage Assays (30-100 μg/ml)
Description
Wild-type, human Aβ1-42 peptide. A number of mutations, identified in the gene encoding the β-amyloid precursor protein (βAPP), have been linked to early-onset Familial Alzheimer’s Disease. Mutations in the genes encoding presenilin 1 and presenilin 2 have also been shown to alter the processing of βAPP, resulting in increased extracellular concentration of β-amyloid peptide Aβ1-42(43) relative to Aβ1-40. Biophysical and biochemical experiments suggest that Aβ1-42(43) may serve as a catalyst for the aggregation and deposition of β-amyloid peptide (Aβ) leading to neurotoxic effects associated with senile plaque formation. Furthermore, antibodies recog-nizing Aβ1-42 revealed that the long form of the peptide is increased in presenilin and βAPP mutants, while other studies have used Aβ specific antibodies to prevent the in vitro fibrillar aggregation of Aβ. Amino acid sequence verified by amino acid analysis or sequencing. This product is supplied in a form that is not neurotoxic prior to a preincubation step. The appearance of toxicity has recently been shown to correlate to the extent of β sheet structure. Useful for neurotoxicity studies and substrate cleavage assays.
Immunogen species
Human
Form
Lyophilized
Formulation
Supplied as a chloride salt.
Recommended reaction conditions
Dissolve the lyophilized peptide at 1 mg/ml in 50 mM Tris-HCl, pH ≥9.0. Dilute peptide to an appropriate concentration with calcium, magnesium-free PBS and incubate at 37°C for 24-48 h prior to neurotoxicity studies. Suggested neurotoxic concentration is 30-100 µg/ml.
